The Diagnostic Value of Soluble Triggering Receptor Expressed on Myeloid Cells for Patients with Acute Stone Pyelonephritis

Basit Öğe Kaydı
dc.authoridBASARALI, Mustafa Kemal/0000-0001-7712-2063
dc.authoridCifci, Aydin/0000-0001-8449-2687
dc.contributor.authorOzsoy, Metin
dc.contributor.authorAtaman, Mirac
dc.contributor.authorSahin, Serhat Kazim
dc.contributor.authorSenocak, Ibrahim
dc.contributor.authorVarlibas, Artuner
dc.contributor.authorYuvanc, Ercan
dc.contributor.authorCifci, Aydin
dc.date.accessioned2025-01-21T16:44:59Z
dc.date.available2025-01-21T16:44:59Z
dc.date.issued2024
dc.departmentKırıkkale Üniversitesi
dc.description.abstractSoluble triggering receptor expressed on myeloid cells (sTREM-1) is a new biomarker that can be used for the diagnosis and monitoring of urinary system infections. This study aimed to evaluate the diagnostic performance of serum sTREM-1 in patients with a diagnosis of acute stone pyelonephritis (ASP). This prospective study included 46 patients with a diagnosis of ASP and a control group of 23 individuals without urinary system infection. Blood samples were taken from participants upon hospital admission, and basal serum sTREM-1 levels were analyzed using the ELISA method. Serum sTREM-1 concentrations were measured after treatment of ASP patients. Basal leukocyte counts, C-reactive protein (CRP) levels, procalcitonin (PCT), and sTREM-1 (98.6 vs. 68.4 pg/mL, p < 0.001) levels were higher in the ASP group compared to the control group. After treatment, the median leukocyte counts, PCT, and sTREM-1 levels decreased and were similar to those of the control group. The median CRP level also decreased after treatment, but it remained higher than that of the control group. In predicting patients with ASP, the baseline sTREM-1 exhibited a sensitivity of 74.6% and a specificity of 78.2%, while its diagnostic performance was lower than that of leukocyte counts, CRP, and PCT. Despite the findings that levels of sTREM-1 were higher upon hospital admission in patients with ASP and significantly decreased after treatment, the utility of sTREM-1 as a biomarker for predicting patients with ASP remains constrained when compared to established inflammatory markers.
dc.identifier.doi10.3390/diagnostics14070777
dc.identifier.issn2075-4418
dc.identifier.issue7
dc.identifier.pmid38611690
dc.identifier.scopus2-s2.0-85190380204
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3390/diagnostics14070777
dc.identifier.urihttps://hdl.handle.net/20.500.12587/25566
dc.identifier.volume14
dc.identifier.wosWOS:001201554500001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofDiagnostics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectbiomarkers; diagnosis; pyelonephritis; soluble triggering receptor expressed on myeloid cells
dc.titleThe Diagnostic Value of Soluble Triggering Receptor Expressed on Myeloid Cells for Patients with Acute Stone Pyelonephritis
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu